国产格列美脲治疗门诊2型糖尿病患者的有效性和安全性评估

Effi cacy and safety of glimepiride made-in China in out-patients with T2DM

目的:研究国产格列美脲治疗门诊2型糖尿病患者的有效性和安全性。方法:华北地区15家三甲医院对门诊血糖控制欠佳的2型糖尿病患者进行问卷调查、查体和实验室检查,按推荐方式应用格列美脲,治疗12周时复测以上指标,分析治疗前后血糖指标和可能的影响因素。结果:治疗后患者的FBS、PBS和HbA1c均明显改善,HbA1c达标率显著提高(20.29%vs 3.57%,P<0.01),低血糖事件发生率0.06%,老年人与青年人例数相当。HbA1c的相关系数由大到小依次为FBS、病程和年龄。结论:对于门诊血糖控制欠佳的2型糖尿病患者,换用或加用国产格列美脲后具有较好的疗效和安全性(包括老年人);格列美脲可联合胰岛素治疗并获得较好的降糖效果;患者治疗后的HbA1c水平与FBS、病程和年龄有关。

Objective： To analyze the efficacy and safety of glimepiride made-in China in out-patients with T2DM.Methods： The T2DM out-patients whose blood glucoses were not well controlled were collected in 15 3rd grade fi rst-class hospitals in Northern China,with the screening of questionnaires,physical examinations and laboratory examinations,and then glimepiride was recommended,reexamines were carried out 12 weeks later.The index of blood glucose before and after the treatment and possible in？ uence factors were analyzed.Results： The levels of FBS,PBS and HbA1c were signifi cantly improved after treatment,with the percentage of patients reaching HbA1c targets increasing greatly（20.29% vs 3.57%,P 0.01） and less hypoglycemic events（0.06%）,the hypoglycemic events happened in elderly were the same as that in the young patients.The coeffi cient correlation related with HbA1c range from high to low were FBS,duration and age.Conclusion： Switching to or adding glimepiride made-in China has high effi cacy and safety on T2DM out-patients with unsatisfactory glucose control,including the elderly.Adding glimepiride to insulin resulted in well improvement of glycemic control.The levels of FBS,duration and age have relations with HbA1c after the treatment.